Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
      Google Scholar   
Citation:
J Clin Oncol vol 40 (16_suppl) 518-518
Meeting Instance:
ASCO 2022
Year:
2022
Type:
Abstract
Sub type:
Poster Discussion
Funding:
AFT
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3905  
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
Pfizer  
Grants:
 
Corr. Author:
 
Authors:
                                       
Networks:
CAPITAL, LAPS-MA036, LAPS-MN026, LAPS-PA015   
Study
AFT-05
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: